Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean M Devlin

Showing results (31-40 of 173) with videos related to

Pageof 18
Sort By:
Leukemia & Lymphoma|January 14, 2016
Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantationHeather Landau, Kevin Wood, David J Chung, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 19, 2017
Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic TransplantationBartlomiej M Getta, Sean M Devlin, Ross L Levine, et al.
Blood Advances|July 8, 2022
Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adultsIoannis Politikos, Carmen Lau, Sean M Devlin, et al.
Blood Advances|August 17, 2022
Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantationMariam T Nawas, Miriam Sanchez-Escamilla, Sean M Devlin, et al.
Transplantation and Cellular Therapy|May 24, 2021
Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell TransplantationNatasia Rodriguez, Jasme Lee, Lisa Flynn, et al.
Blood|March 12, 2015
Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphomaCraig S Sauter, Matthew J Matasar, Jessica Meikle, et al.
Bone Marrow Transplantation|February 13, 2024
Immune reconstitution, vaccine responses, and rituximab use after ex-vivo CD34-selected myeloablative allogenic hematopoietic cell transplantationGiovanna Melica, Elaina Preston, Meighan Palazzo, et al.
Bone Marrow Transplantation|February 20, 2022
Ionizing radiation exposure after allogeneic hematopoietic cell transplantationChristina Cho, Molly A Maloy, Sean M Devlin, et al.
Cancer Immunology Research|October 15, 2015
T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of ImmunotherapyDavid J Chung, Katherine B Pronschinske, Justin A Shyer, et al.
Leukemia & Lymphoma|June 23, 2019
Feasibility of a patient-reported, electronic geriatric assessment tool in hematopoietic cell transplantation - a single institution pilot studyRichard J Lin, Parastoo B Dahi, Armin Shahrokni, et al.
Pageof 18

Showing results (31-40 of 173) with videos related to

Sort By:
Pageof 18
Leukemia & Lymphoma|January 14, 2016
Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantationHeather Landau, Kevin Wood, David J Chung, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 19, 2017
Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic TransplantationBartlomiej M Getta, Sean M Devlin, Ross L Levine, et al.
Blood Advances|July 8, 2022
Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adultsIoannis Politikos, Carmen Lau, Sean M Devlin, et al.
Blood Advances|August 17, 2022
Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantationMariam T Nawas, Miriam Sanchez-Escamilla, Sean M Devlin, et al.
Transplantation and Cellular Therapy|May 24, 2021
Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell TransplantationNatasia Rodriguez, Jasme Lee, Lisa Flynn, et al.
Blood|March 12, 2015
Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphomaCraig S Sauter, Matthew J Matasar, Jessica Meikle, et al.
Bone Marrow Transplantation|February 13, 2024
Immune reconstitution, vaccine responses, and rituximab use after ex-vivo CD34-selected myeloablative allogenic hematopoietic cell transplantationGiovanna Melica, Elaina Preston, Meighan Palazzo, et al.
Bone Marrow Transplantation|February 20, 2022
Ionizing radiation exposure after allogeneic hematopoietic cell transplantationChristina Cho, Molly A Maloy, Sean M Devlin, et al.
Cancer Immunology Research|October 15, 2015
T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of ImmunotherapyDavid J Chung, Katherine B Pronschinske, Justin A Shyer, et al.
Leukemia & Lymphoma|June 23, 2019
Feasibility of a patient-reported, electronic geriatric assessment tool in hematopoietic cell transplantation - a single institution pilot studyRichard J Lin, Parastoo B Dahi, Armin Shahrokni, et al.
Pageof 18